268 related articles for article (PubMed ID: 10942927)
61. NOPE for relapsed aggressive diffuse non-Hodgkin's lymphoma.
Bezwoda WR; Bezwoda MA; Seymour L; Dansey R; Ariad S
Leuk Lymphoma; 1993 Jul; 10(4-5):329-33. PubMed ID: 8220131
[TBL] [Abstract][Full Text] [Related]
62. A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly.
Bellesi G; Rigacci L; Alterini R; Bernardi F; Stefanacci S; Innocenti F; Fusco II; Longo G; Di Lollo S; Ferrini PR
Leuk Lymphoma; 1996 Feb; 20(5-6):475-80. PubMed ID: 8833406
[TBL] [Abstract][Full Text] [Related]
63. Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma.
Hopfinger G; Heinz R; Koller E; Schneider B; Pittermann E
Eur J Haematol; 1995 Oct; 55(4):223-7. PubMed ID: 7589338
[TBL] [Abstract][Full Text] [Related]
64. Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Plattel WJ; Kluin-Nelemans HC; de Bock GH; van Imhoff GW
Bone Marrow Transplant; 2011 Jun; 46(6):827-34. PubMed ID: 20729926
[TBL] [Abstract][Full Text] [Related]
65. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
Gregory SA; Vose J; Modiano M; Kraemer K; Rifkin R; Rubin A; Menduni T; Ghalie R
Leuk Lymphoma; 2001 Jan; 40(3-4):315-24. PubMed ID: 11426553
[TBL] [Abstract][Full Text] [Related]
66. Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Itoh K; Igarashi T; Ohtsu T; Wakita H; Watanabe Y; Fujii H; Minami H; Sasaki Y
Int J Hematol; 1998 Dec; 68(4):431-7. PubMed ID: 9885442
[TBL] [Abstract][Full Text] [Related]
67. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
Robak T; Góra-Tybor J; Lech-Marańda E; Błoński JZ; Kasznicki M
Eur J Haematol; 2001 Mar; 66(3):188-94. PubMed ID: 11350487
[TBL] [Abstract][Full Text] [Related]
68. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin.
Oztürk MA; Barişta I; Altundağ MK; Türker A; Yalçin S; Celik I; Güllü I; Güler N; Ozişik Y; Kars A; Kansu E; Baltali E; Tekuzman G
Chemotherapy; 2002 Dec; 48(5):252-8. PubMed ID: 12476042
[TBL] [Abstract][Full Text] [Related]
69. [Efficacy and survival analysis of DICE regimen for 97 patients with relapsed or refractory Non-Hodgkin's lymphoma].
Ping LY; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ying ZT; Liu WP; Zhang C; Deng LJ; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):790-794. PubMed ID: 27719723
[TBL] [Abstract][Full Text] [Related]
70. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma.
Tirelli U; Zagonel V; Errante D; Serraino D; Talamini R; De Cicco M; Carbone A; Monfardini S
J Clin Oncol; 1992 Feb; 10(2):228-36. PubMed ID: 1732423
[TBL] [Abstract][Full Text] [Related]
71. Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
Tseng YD; Chen YH; Catalano PJ; Ng A
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):223-31. PubMed ID: 25835625
[TBL] [Abstract][Full Text] [Related]
72. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma.
Salvagno L; Contu A; Bianco A; Endrizzi L; Schintu GM; Olmeo N; Aversa SM; Chiarion-Sileni V; Sorarù M; Fiorentino MV
Ann Oncol; 1992 Dec; 3(10):833-7. PubMed ID: 1286045
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
Nabhan C; Davis N; Bitran JD; Galvez A; Fried W; Tolzien K; Foss S; Dewey WM; Venugopal P
Cancer; 2011 Apr; 117(7):1490-7. PubMed ID: 21425150
[TBL] [Abstract][Full Text] [Related]
74. CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma.
Walewski J; Krzyzanowska JB; Kraszewska E; Lampka E; Romejko-Jarosińska J; Miśkiewicz Z; Meder J
Med Oncol; 2000 Aug; 17(3):195-202. PubMed ID: 10962530
[TBL] [Abstract][Full Text] [Related]
75. Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma.
Haim N; Ben-Shahar M; Faraggi D; Tsuri-Etzioni A; Leviov M; Epelbaum R
Cancer; 1997 Nov; 80(10):1989-96. PubMed ID: 9366303
[TBL] [Abstract][Full Text] [Related]
76. Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
Aurer I; Mitrović Z; Nemet D; Radman I; Sertić D; Serventi-Seiwerth R; Stern-Padovan R; Santek F; Nola M; Mrsić M; Labar B
J Chemother; 2008 Oct; 20(5):640-4. PubMed ID: 19048695
[TBL] [Abstract][Full Text] [Related]
77. A pilot study on the use of outpatient fractionated ifosfamide, carboplatin and etoposide (ICE) and pegfilgrastim as a salvage and mobilizing regimen for relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
George B; Benson W; Hertzberg MS
Bone Marrow Transplant; 2012 Jul; 47(7):1001-2. PubMed ID: 22002487
[No Abstract] [Full Text] [Related]
78. Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.
Abdayem P; Ibrahim N; El Dakdouki Y; Willekens C; Ghez D; A Rouche J; Dartigues P; Desmaris R; Danu A; Rossignol J; Lazarovici J; Fermé C; Ribrag V; Michot JM
Eur J Haematol; 2021 Apr; 106(4):574-583. PubMed ID: 33512026
[TBL] [Abstract][Full Text] [Related]
79. Effective salvage chemotherapy in relapsed or refractory non-Hodgkin's lymphoma.
Buzzoni R; Colleoni M; Bajetta E; Nolè F; Nelli P; De Palma CA; de Braud F
Ann Oncol; 1993 Mar; 4(3):251-3. PubMed ID: 8471558
[TBL] [Abstract][Full Text] [Related]
80. ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.
Park SH; Kim S; Ko OB; Koo JE; Lee D; Jeong YP; Huh J; Kim SB; Kim SW; Lee JL; Suh C
Korean J Intern Med; 2006 Sep; 21(3):159-64. PubMed ID: 17017664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
